Results 211 to 220 of about 295,380 (280)

Fungus Before the Fire: Cryptococcal Meningitis Reveals Underlying Follicular Lymphoma. [PDF]

Ann Indian Acad Neurol
Dixit Y, Goel A, Chatterjee D, Mahesh KV.   +3 more
europepmc   +1 more source

Trained Immunity in Childhood Vaccination

Acta Paediatrica, Volume 115, Issue 11, Page 2402-2413, November 2026.
Trained immunity as an emerging concept in paediatric vaccinology. Trained immunity links vaccine stimuli through epigenetic and metabolic reprogramming to enhanced innate immune cell function, thereby strengthening protection against diverse pathogens while promoting adaptive immune responses through more efficient antigen presentation and co ...
ChenRongRong Cai, Lubnaa Hossenbaccus, Eva Kaufmann   +2 more
wiley   +1 more source

Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes. [PDF]

Hum Vaccin Immunother
Shouse G.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis. [PDF]

Br J Haematol
Caracciolo D, Lombardo MR, Reitano G, Napoli C, Fiorillo L, Callerame C, Garritano M, Bulotta A, Munir M, Pensabene G, Barbieri E, Bavieri A, Tassone P, Tagliaferri P, Luminari S.   +14 more
europepmc   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, Volume 117, Issue 11, Page 3098-3107, November 2026.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

Intrafollicular PAI-1 Expression Is Associated with Absence of Histological Transformation During Long-Term Follow-Up in Follicular Lymphoma. [PDF]

Int J Mol Sci
Dohrmann C, Enemark MH, Jensen CMS, Lauridsen KL, Plesner TL, Hamilton-Dutoit SJ, Ludvigsen M.   +6 more
europepmc   +1 more source

Application of Mechanistic Modeling to Support Dose‐Relevant Decision Making for CAR‐T Cell Therapy in Oncology: A Systematic Scoping Review

Clinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT CAR‐T therapy has improved outcomes in selected relapsed or refractory hematologic malignancies. However, rational dose‐relevant decision application remains challenging because the administered (nominal) cell dose does not reliably predict in vivo exposure, toxicity, or clinical response.
Dolapo Odujinrin, Graham McClelland
wiley   +1 more source

Spontaneous Metabolic Regression in High-Burden Follicular Lymphoma: A Case Report. [PDF]

Case Rep Hematol
Bronstein Y, Vitkon R, Hayman L, Perry C.   +3 more
europepmc   +1 more source

Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer

International Journal of Cancer, Volume 159, Issue 8, Page 1974-1989, 15 October 2026.
Although lenvatinib is the current first‐line therapy for radioiodine‐refractory differentiated thyroid carcinoma, its use is limited by severe side effects and reduced sensitivity. Here, the authors assessed the potential of sensitizing differentiated thyroid carcinoma tumor cells with limited lenvatinib responsiveness through the administration of ...
Celina Ablinger, Petra Huber‐Cantonati, Daniela D. Weber, Sarah Pichler, Georg Schischkow, Marta Garcia‐Miralles, Christian Pirich, Gundula Rendl, Teresa Kiener, Thomas Felder, Martin Geroldinger, Robert Terkola, Barbara Kofler, Johanna Pachmayr   +13 more
wiley   +1 more source